XEOMIN (incobotulinumtoxinA) Safety Profile in the Treatment of Adult Upper Limb Spasticity

Proven safety in the treatment of adult ULS

  • In 2 clinical trials, with total doses of 400 units, no adverse reactions (ARs) occurred in more than 3% of patients1
  • Most ARs were mild to moderate2,3

aes_uls

Pivotal Safety and Efficacy Trial

Secondary Safety Study

kanovskychart
References

  1. XEOMIN® [package insert]. Raleigh, NC: Merz North America, Inc; 2015.
  2. Elovic EP, Munin MC, Kanovsky P, Hanschmann A, Hiersemenzel R, Marciniak C. Randomized, placebo-controlled trial of incobotulinumtoxinA for upper-limb post-stroke spasticity [published online ahead of print]. Muscle Nerve. doi: 10.1002/mus.24776.
  3. Kanovsky P, Slawek J, Denes Z, et al. Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol. 2009;32(5):259-265.